Fig. 7
From: MIR210HG promotes breast cancer progression by IGF2BP1 mediated m6A modification
MYCN regulates MIR210HG via IGF2BP1. A MYCN ChIP-Seq analysis on IGF2BP1 promoter. Three independent ChIP-Seq datasets were obtained from Cistrome DB. E-box was indicated in IGF2BP1 genome scheme. B and C Unpaired and paired analysis of MYCN expression in TCGA-BRCA. In unpaired analysis, 1109 tumor samples and 113 normal samples were included. In paired analysis, 112 tumor samples and 112 normal samples were included. D Pearson correlation analysis between MYCN expression and IGF2BP1 expression in breast cancer patients. E MYCN-IGF2BP1 target was validated by q-ChIP analysis. F Mutation strategy of E-Box in IGF2BP1 promoter for luciferase assay. G MYCN-IGF2BP1 target was validated by luciferase assay analysis. H and I q-PCR and western blot analysis on IGF2BP1 when MYCN was induced by DOX in MCF-7MYCN−HA−OV cell. J Xenograft tumors of 4 groups: scrambled siRNA and Dox treated 231MYCN−HA−OV cell; IGF2BP1 siRNA and Dox treated 231MYCN−HA−OV cell; scrambled siRNA 231MYCN−HA−OV cell; IGF2BP1 siRNA 231MYCN−HA−OV cell. K and L Xenograft tumor weight and volume were measured. M q-PCR analysis on MIR210HG after MYCN was induced by Dox treatment in MCF-7MYCN−HA−OV cell. N Western blot analysis on IGF2BP1 with indicated treatments. O q-PCR analysis on MIR210HG and miR-210 after treated with DOX or IGF2BP1 siRNA as indicated in MCF-7MYCN−HA−OV cell. P Pearson correlation analysis between MYCN expression and MIR210HG expression in breast cancer patients. **p < 0.01, ***p < 0.001